Information Provided By:
Fly News Breaks for July 20, 2017
ABBV
Jul 20, 2017 | 07:54 EDT
Credit Suisse analyst Vamil Divan raised his price target for AbbVie to $74 from $65 ahead of Q2 results. The analyst reiterates a Neutral rating on the shares as he believes the company's strong near-term growth profile is offset by questions over Humira's longevity and sees the risk/reward around other pipeline assets as being balanced.